Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC
- Conditions
- Non-muscle Invasive Bladder Cancer (NMIBC)
- Interventions
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2020-08-19
- Lead Sponsor
- Anchiano Therapeutics Israel Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT03719300
- Locations
- 🇺🇸
Alaska Urological Institute, Anchorage, Alaska, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
Pilot Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma
- Conditions
- Transitional Cell Carcinoma of Bladder
- Interventions
- First Posted Date
- 2013-06-14
- Last Posted Date
- 2019-03-11
- Lead Sponsor
- Anchiano Therapeutics Israel Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT01878188
- Locations
- 🇮🇱
Bnai Zion MC, Haifa, Israel
🇮🇱Carmel Medical Center, Haifa, Israel
🇮🇱Wolfson Medical Center, Holon, Israel
Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma
- Conditions
- Pancreas, Adenocarcinoma
- First Posted Date
- 2011-08-10
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- Anchiano Therapeutics Israel Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT01413087
- Locations
- 🇺🇸
Winthrop University Hospital, Mineola, New York, United States
🇺🇸Thomas Jefferson University, Philadelphia, Pennsylvania, United States
🇺🇸Joe Arrington Cancer Research & Treatment Center, Lubbock, Texas, United States
Phase 1/2a Study of DTA-H19 in Advanced Stage Ovarian Cancer
- Conditions
- Ovarian Cancer
- First Posted Date
- 2009-01-21
- Last Posted Date
- 2019-06-13
- Lead Sponsor
- Anchiano Therapeutics Israel Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT00826150
- Locations
- 🇮🇱
The Edith Wolfson Medical Center, Holon, Israel
🇮🇱Hadassah University Hospital, Jerusalem, Israel
🇮🇱Meir Hospital, Kfar Saba, Israel
Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer
- Conditions
- Pancreatic Neoplasms
- First Posted Date
- 2008-07-09
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- Anchiano Therapeutics Israel Ltd.
- Target Recruit Count
- 9
- Registration Number
- NCT00711997
- Locations
- 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States
🇮🇱Hadassah University Hospital, Jerusalem, Israel
🇮🇱Meir Hospital, Kfar Saba, Israel
- Prev
- 1
- 2
- Next